V-ATPase in cancer progression: Two sides of the same coin
V-ATPase in cancer progression: Two sides of the same coin |
https://doi.org/10.18632/oncotarget.26218
Mohd Saqib,
and Bibhuti B. Mishra
|
35197-35198 |
Clinical application of cfDNA: moving in the right direction, but still a long way to go
Clinical application of cfDNA: moving in the right direction, but still a long way to go |
https://doi.org/10.18632/oncotarget.26224
Shehara Mendis,
and Jonathan M. Loree
|
35199-35200 |
Mutant molecular chaperone activates cytokine receptor as a homomultimer
Mutant molecular chaperone activates cytokine receptor as a homomultimer |
https://doi.org/10.18632/oncotarget.26221
Marito Araki,
and Norio Komatsu
|
35201-35202 |
ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells
ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells |
https://doi.org/10.18632/oncotarget.26230
Daichi Inoue,
Takeshi Fujino,
and Toshio Kitamura
|
35203-35204 |
Rise of the specialized onco-ribosomes
Rise of the specialized onco-ribosomes |
https://doi.org/10.18632/oncotarget.26231
Kim R. Kampen,
Sergey O. Sulima,
and Kim De Keersmaecker
|
35205-35206 |
Biothiols and oxidative stress markers and polymorphisms of TOMM40 and APOC1 genes in Alzheimer's disease patients
Biothiols and oxidative stress markers and polymorphisms of TOMM40 and APOC1 genes in Alzheimer's disease patients |
https://doi.org/10.18632/oncotarget.26184
Michal Prendecki,
Jolanta Florczak-Wyspianska,
Marta Kowalska,
Jan Ilkowski,
Teresa Grzelak,
Katarzyna Bialas,
Malgorzata Wiszniewska,
Wojciech Kozubski,
and Jolanta Dorszewska
|
35207-35225 |
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models |
https://doi.org/10.18632/oncotarget.26215
Sunkyu Kim,
Ralph Tiedt,
Alice Loo,
Thomas Horn,
Scott Delach,
Steven Kovats,
Kristy Haas,
Barbara Schacher Engstler,
Alexander Cao,
Maria Pinzon-Ortiz,
Iain Mulford,
Michael G. Acker,
Rajiv Chopra,
Christopher Brain,
Emmanuelle di Tomaso,
William R. Sellers,
and Giordano Caponigro
|
35226-35240 |
Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state
Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state |
https://doi.org/10.18632/oncotarget.26235
Elena V. Skvortsova,
Sergey A. Sinenko,
and Alexey N. Tomilin
|
35241-35250 |
Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors
Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors |
https://doi.org/10.18632/oncotarget.25834
Alessandro Ottaiano,
Valerio Scotti,
Chiara De Divitiis,
Monica Capozzi,
Carmen Romano,
Antonino Cassata,
Rossana Casaretti,
Lucrezia Silvestro,
Anna Nappi,
Valeria Vicario,
Alfonso De Stefano,
Salvatore Tafuto,
Massimiliano Berretta,
Guglielmo Nasti,
and Antonio Avallone
|
35251-35265 |
Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors
Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors |
https://doi.org/10.18632/oncotarget.26186
Juliette Servante,
Jasper Estranero,
Lisethe Meijer,
Rob Layfield,
and Richard Grundy
|
35266-35277 |
ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report
ROS1-rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report |
https://doi.org/10.18632/oncotarget.26233
Masaya Taniwaki,
Masahiro Yamasaki,
Koto Kawata,
Kazuma Kawamoto,
Kunihiko Funaishi,
Yu Matsumoto,
Naoko Matsumoto,
Nobuyuki Ohashi,
and Noboru Hattori
|
35278-35282 |
Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor |
https://doi.org/10.18632/oncotarget.26252
Zexi Hu,
Yong Hu,
Xicheng Liu,
Rongwen Xi,
Aiqun Zhang,
Deruo Liu,
Qiang Xie,
and Liang Chen
|
35283-35283 |
Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer |
https://doi.org/10.18632/oncotarget.26254
Naiqing Xu,
Wenfeng Fang,
Libing Mu,
Yanna Tang,
Lei Gao,
Shengxiang Ren,
Dengfeng Cao,
Lixin Zhou,
Aiqun Zhang,
Deruo Liu,
Caicun Zhou,
Kwok-Kin Wong,
Lei Yu,
Li Zhang,
and Liang Chen
|
35284-35284 |
Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment
Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment |
https://doi.org/10.18632/oncotarget.26255
Hongjuan Zhang,
Cheng Zhan,
Ji Ke,
Zhiqiang Xue,
Aiqun Zhang,
Kaifeng Xu,
Zhirong Shen,
Lei Yu,
and Liang Chen
|
35285-35285 |
Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity
Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity |
https://doi.org/10.18632/oncotarget.26258
Kelly K. Haagenson,
Jessica Wei Zhang,
Zhengfan Xu,
Malathy P.V. Shekhar,
and Gen Sheng Wu
|
35286-35286 |